Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beryl DrugsBOM:524606 +7.85%68 EBITDA Margin % is 26.12% as of Mar. 2026, which is 161% above its 10-year median of 9.99. GuruFocus rates BOM:524606 with a GF Score™ of 68/100 and a GF Value™ of ₹20.66 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Beryl Drugs ranks better than 51.93% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Beryl Drugs's EBITDA for the
three
months ended in Mar. 2026 was ₹13.4 Mil. Beryl Drugs's Revenue for the
three
months ended in Mar. 2026 was ₹51.3 Mil. Therefore, Beryl Drugs's EBITDA margin for the quarter that ended in Mar. 2026 was 26.12%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Beryl Drugs EBITDA Margin % Related Terms
Beryl Drugs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Beryl Drugs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beryl Drugs EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Beryl Drugs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beryl Drugs (BOM:524606) has a EBITDA Margin % of 26.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beryl Drugs and its competitors. This is 161% above median its historical median of 9.99. Over the past decade, Beryl Drugs' EBITDA Margin % has ranged from 1.72 to 14.80. According to the industry distribution chart, Beryl Drugs ranks #461 out of 959 companies in the Drug Manufacturers industry, placing it in the top 48.1%.
Is Beryl Drugs' EBITDA Margin % too high?
Beryl Drugs' current EBITDA Margin % of 26.12% is 161% above median its 10-year median of 9.99. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 14.80. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Beryl Drugs' value of 26.12% is 115.7% above this industry median. Based on the distribution chart, Beryl Drugs ranks #461 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beryl Drugs has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beryl Drugs' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beryl Drugs ranks #461 out of 959 companies for EBITDA Margin %. This puts Beryl Drugs in the upper half of its industry. The industry median EBITDA Margin % is 12.11. Beryl Drugs' value of 26.12% is 115.7% above this benchmark. Historically, Beryl Drugs' own EBITDA Margin % has ranged from 1.72 to 14.80 over the past decade. While the company's 10-year median is 9.99 vs. the industry median of 12.11, Beryl Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beryl Drugs's current EBITDA Margin % of 26.12% is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beryl Drugs and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beryl Drugs's current EBITDA Margin % is 26.12%, which is 161% above median its own 10-year median of 9.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beryl Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beryl Drugs (BOM:524606) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹20.66, compared to a current price of ₹24.04 — trading 16.4% above its estimated fair value. The current EBITDA Margin % is 26.12%, which is 161% above median its 10-year median of 9.99 and 115.7% above the Drug Manufacturers industry median of 12.11. Beryl Drugs' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Beryl Drugs (BOM:524606), the current EBITDA Margin % is 26.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beryl Drugs (BOM:524606) Overvalued in 2026?
Based on GuruFocus' analysis, Beryl Drugs stock appears to be overvalued.
The current stock price of ₹24.04 is trading 16.4% above its estimated GF Value™ of ₹20.66.
GuruFocus considers Beryl Drugs to be Modestly Overvalued.
Key valuation signals for BOM:524606:
EBITDA Margin %: 26.12% (161% above median its 10-year median of 9.99)
GF Value™: ₹20.66 vs. price of ₹24.04 (16.4% above fair value)
Industry Position: 115.7% above the Drug Manufacturers median (#461 of 959)
No single metric tells the full story. See the BOM:524606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.
68GF Score
Get the complete analysis for BOM:524606
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524606 has been successfully added to your 
